Candel Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| DECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $102,654 | $35,413 |
| Prepaid expenses and other current assets | 1,150 | 1,384 |
| Total current assets | 103,804 | 36,797 |
| Fixed assets, net | 2,191 | 3,206 |
| Lease right of use assets | 542 | 816 |
| Restricted cash | 266 | 266 |
| Other assets | 63 | 116 |
| Total assets | $106,866 | $41,201 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $237 | $422 |
| Accrued expenses | 5,113 | 4,356 |
| Current portion of term loan payable to a bank | 9,895 | 8,893 |
| Current portion of lease liability | 566 | 513 |
| Warrant liability | 21,718 | — |
| Total current liabilities | 37,529 | 14,184 |
| Term loan payable to a bank | 1,733 | 11,632 |
| Other long-term debt | 870 | 751 |
| Lease liability, net of current portion | 407 | 973 |
| Warrant liability | — | 916 |
| Total liabilities | 40,539 | 28,456 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued or outstanding at December 31, 2024 and 2023, respectively. | — | — |
| Common stock, $0.01 par value; 150,000,000 shares authorized at December 31, 2024 and 2023; 46,933,088 and 29,213,627 shares issued at December 31, 2024 and 2023, respectively; and 46,810,480 and 29,091,019 shares outstanding at December 31, 2024 and 2023, respectively. | 469 | 290 |
| Treasury stock (at cost) | (448) | (448) |
| Additional paid-in capital | 258,511 | 149,931 |
| Accumulated deficit | (192,205) | (137,028) |
| Total stockholders’ equity | 66,327 | 12,745 |
| Total liabilities and stockholders’ equity | $106,866 | $41,201 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.